Compare Equinor ASA (EQNR) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs Zoetis Inc — how do they compare? Equinor ASA trades at $40.95 (market cap $97.58B), while Zoetis Inc trades at $73.7 (market cap $31.14B). The key difference: Equinor ASA is far larger — about 3.1× Zoetis Inc's market cap, and Equinor ASA pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| EQNR | ZTS | |
|---|---|---|
Market Cap | $97.58B | $31.14B |
Sector | Energy | Health |
52-Week High | $42.40 | $156.76 |
52-Week Low | $22.41 | $71.91 |
Enterprise Value | $106.28B | $38.70B |
Dividend Yield | 3.81% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinor (EQNR) trades at $40.92, down slightly by 0.17% on the day, with strong technical momentum showing a bullish moving average signal. The company delivered mixed Q2 2026 earnings with a revenue beat but EPS miss, while maintaining robust cash flow generation and shareholder returns through dividends and buybacks. Recent news highlights strong quarterly performance driven by higher energy prices and production growth.
EQNR presents a compelling value case with attractive valuation multiples (P/E 11.09, EV/EBITDA 2.3) and solid profitability metrics (ROE 21.32%). However, declining profit margins from 19.29% in 2022 to 4.76% in 2025 and analyst caution (56.53% hold rating) suggest balanced risk-reward. The stock offers income potential with consistent dividends amid energy market volatility.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
